Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shorts are covering:
Repros Therapeutics Inc. - Common Stock
Settlement Date Short Interest Percent Change Average Daily Share Volume Days to Cover
10/15/2008 1,081,177 (10.86) 48,327 22.37
09/30/2008 1,212,861 (4.52) 98,358 12.33
09/15/2008 1,270,224 46.99 121,621 10.44
08/29/2008 864,144 61.84 70,305 12.29
http://www.nasdaqtrader.com/trader.aspx?id=ShortInterest
You know, I've never heard an explanation of why institutions must publicly divulge their long positions - but not not their short positions. Is there one?
Short Interest dropped 4.52%
Repros Therapeutics Inc. - Common Stock
Settlement Date Short Interest Percent Change Average Daily Share Volume Days to Cover
09/30/2008 1,212,861 (4.52) 98,358 12.33
09/15/2008 1,270,224 46.99 121,621 10.44
08/29/2008 864,144 61.84 70,305 12.29
08/15/2008 533,942 18.72 56,575 9.44
07/31/2008 449,758 35.49 73,583 6.11
07/15/2008 331,957 (0.23) 70,781 4.69
06/30/2008 332,729 (47.94) 50,158 6.63
06/13/2008 639,126 (24.99) 137,404 4.65
05/30/2008 852,103 (10.73) 62,820 13.56
05/15/2008 954,511 (6.56) 42,288 22.57
04/30/2008 1,021,502 3.04 54,807 18.64
04/15/2008 991,404 1.25 71,296 13.91
03/31/2008 979,155 (22.12) 113,826 8.60
03/14/2008 1,257,186 8.24 115,126 10.92
02/29/2008 1,161,472 0.86 59,932 19.38
02/15/2008 1,151,580 (9.95) 55,279 20.83
01/31/2008 1,278,783 (7.91) 77,639 16.47
01/15/2008 1,388,551 17.07 61,643 22.53
12/31/2007 1,186,120 35.63 128,710 9.22
12/14/2007 874,526 57.68 273,273 3.20
11/30/2007 554,631 39.90 111,740 4.96
11/15/2007 396,460 32.81 94,349 4.20
10/31/2007 298,519 16.80 136,913 2.18
10/15/2007 255,571 (15.32) 80,905 3.16
I recall that JP said on a past CC that enrollment in the anemia p3's was slow. Has anybody heard anything since then? Perhaps results by the end of 2008 is overly optimistic?
""The 2.4 million new shares will be placed with existing shareholders that are not short the stock. It is widely understood, IMO, that most or all of these will be going to Efficacy.""
> Mr. Borg.....
> I will believe it when I see it.
A very poorly timed post.
I also see that David Miller has posted an article on Minyanville about today's news:
http://www.minyanville.com/articles/biotech-finance-rprx-short-squeeze-repro/index/a/19225/from/yahoo
Short interest up big:
Repros Therapeutics Inc. - Common Stock
Settlement Date Short Interest Percent Change Average Daily Share Volume Days to Cover
09/15/2008 1,270,224 46.99 121,621 10.44
08/29/2008 864,144 61.84 70,305 12.29
08/15/2008 533,942 18.72 56,575 9.44
07/31/2008 449,758 35.49 73,583 6.11
07/15/2008 331,957 (0.23) 70,781 4.69
06/30/2008 332,729 (47.94) 50,158 6.63
06/13/2008 639,126 (24.99) 137,404 4.65
05/30/2008 852,103 (10.73) 62,820 13.56
05/15/2008 954,511 (6.56) 42,288 22.57
04/30/2008 1,021,502 3.04 54,807 18.64
04/15/2008 991,404 1.25 71,296 13.91
03/31/2008 979,155 (22.12) 113,826 8.60
03/14/2008 1,257,186 8.24 115,126 10.92
02/29/2008 1,161,472 0.86 59,932 19.38
02/15/2008 1,151,580 (9.95) 55,279 20.83
01/31/2008 1,278,783 (7.91) 77,639 16.47
01/15/2008 1,388,551 17.07 61,643 22.53
12/31/2007 1,186,120 35.63 128,710 9.22
12/14/2007 874,526 57.68 273,273 3.20
11/30/2007 554,631 39.90 111,740 4.96
11/15/2007 396,460 32.81 94,349 4.20
10/31/2007 298,519 16.80 136,913 2.18
10/15/2007 255,571 (15.32) 80,905 3.16
09/28/2007 301,798 (5.88) 61,483 4.91
The 2.4 million new shares will be placed with existing shareholders that are not short the stock. It is widely understood, IMO, that most or all of these will be going to Efficacy.
I hope our new friend Hptaxis is enjoying the weather down there in Houston. Have a great day Hptaxis!
io - this sleazy character clearly has an agenda here. I'd like to know why someone doing research in the same space spends so much time bashing a company that obviously has so little going for it.
They need to get this damn financing out of the way before the shareprice drops any more.
A quick read of the HPT/Axis website shows they work on hormone pathways related to mens health issues. This would suggest you are only interested in androxal? I also see that both HPT/Axis and Repros are located in the Houston area. And you don't already know each other?
> As a calibration of my expectations, I give it an 80% chance of greater than $35M in 09Q1.
Better yet, what do you forecast for 4Q08? And I agree with you that slow uptake was to be expected, given the process of getting into hospital formularies. Next quarters numbers should be more telling, but I don't think we'll be able to say one way or another til mid-09.
I haven't listened to today's presentations yet, but why all the long faces? The only negative news I have read about is the slow enrollment of the anemia p3s. Or is it about more timeline slippage and the lack of price appreciation and low volume following Analyst Day?
> hard to believe it's another disappointed former large holder. seems more like there's a better or an additional explanation for the pps behavior.
I'm really getting tired of that explanation for every price drop. Makes me wonder if biotech is investable any more.
Repros Therapeutics Inc. Announces That Initial Findings for Proellex® Show No Tumorigenic Response in a Two-year Carcinogenicity Study in Rats
THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) today released initial findings from evaluation of gross necropsies conducted upon completion of the in-life portion of a two-year study conducted to satisfy the balance of the FDA mandated two-species trials to demonstrate the lack of carcinogenic potential for new chemical entities. In a controlled study conducted at MPI Research of Mattawan, MI, Proellex® showed no potential for tumor induction as compared to controls in the gross findings. Proellex or the same solution without drug (vehicle) was given orally every day to male and female rats for two years. Males were examined earlier and individual tissues showed no dose dependent cancer lesions as compared to controls. Female rats were treated at 20, 70 and 200 times the human dose in this two-year study. Gross necropsy of female rats given the equivalence of a life-time exposure to Proellex demonstrates that Proellex is not a carcinogen based on the lack of gross tumor findings as compared to controls. Tissues removed at necropsy are currently undergoing microscopic evaluation. A final determination of carcinogenic potential is pending.
In a mouse carcinogenicity study of Proellex previously reported in June of 2008 performed at BioReliance in Rockville, Maryland there were similarly no gross cancer tumors in initial gross observations. Those studies used a breed of mice bearing the rasH2 mutation, rendering them genetically primed for the development of tumors when treated with carcinogens. The positive control group treated with urethane showed such tumors, as expected. Male and female animals treated with multiple doses of Proellex® for 26 weeks were evaluated for cancers compared to a negative control material that received neither urethane nor Proellex®. A gross examination revealed no apparent tumorigenic response to Proellex. Tissues are currently undergoing microscopic evaluation.
In a previously completed battery of studies, Proellex showed no genotoxic activity, an early indicator of potential for induction of cancerous tumors. In most cases the lack of dose dependent gross tumor findings compared to controls provides strong evidence for the lack of carcinogenic potential.
Joseph S. Podolski commented, “We are pleased with the continued excellent progress being made in our NDA program for Proellex. The lack of evidence of cancer induction is a very favorable response and consistent with our observations of the anti-proliferative and pro-apoptotic properties of the drug. Pending the microscopic evaluations of these two carcinogenicity studies we will have satisfied the FDA’s requirement for assessing the carcinogenic potential for our lead drug Proellex. This is a major component of our NDA filing. We will continue to provide timely updates to our shareholders as additional data becomes available.”
Repros Therapeutics Inc. Announces That Proellex(R) Administered to Patients as Cyclic Therapy to Treat the Symptoms of Uterine Fibroids for Up to 30 Months Shows No Adverse Effects on the Endometrium
Wednesday July 16, 5:43 pm ET
THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) today released strong results from its completed extension safety study of Proellex in the chronic treatment of the symptoms associated with uterine fibroids. To date there have been no abnormal histological findings from the endometrial biopsies taken post menses after cessation of drug administration.
ADVERTISEMENT
As of this release, results from 13 women who had endometrial biopsies post menses following last dose of drug in a two-drug cycle extension study of Proellex in the treatment of symptoms associated with uterine fibroids are available. These women have been exposed to Proellex for one three-month and two four-month drug cycles to help control the symptoms of their uterine fibroids. These three cycles have covered a span of two and one half years which exceeds current FDA guidance for the duration of exposure to hormonal drugs.
The biopsies have been read by a panel of three expert pathologists all of whom will remain blinded to the treatment allocations until all of the final biopsies from this study have been read. The panel is led by Dr. George Mutter, Associate Professor of Pathology at Harvard Medical School, Department of Pathology, Brigham and Women’s Hospital. Dr. Mutter is a leading expert in the interpretation of gynecological histology and pathology.
Results of assessments of the post menses tissues are that of a benign endometrium. While previous end of drug cycle biopsies from these subjects all had histological changes consistent with those induced by progesterone receptor modulators (Proellex class of drugs), none of these post drug cessation biopsies reflected any of those histological changes. These key findings indicate that the effects of Proellex on the endometrium are present during drug exposure and are reversible upon cessation of drug treatment.
Repros has described in previous communications that it had developed a unique approach to dosing with Proellex which treats women for four months (16 weeks) and then stops treatment to create an “off drug interval” until the next menstrual period commences at which time treatment recommences for four months. These cyclical treatments are designed to be used for chronic treatment of symptomatic uterine fibroids and endometriosis. The rationale for this treatment regimen is that most of the reported bleeding events in previous studies occurred after 16 weeks of continuous treatment and were accompanied by endometrial thickening. By allowing a menstrual flow to occur after treatment withdrawal, the endometrium is essentially refreshed and the tendency toward a progressive endometrial thickening eliminated.
Joseph S. Podolski commented, “The importance of these findings can not be overstated. We believe this is a key finding. The consistency of endometrial effects on and off Proellex are strong and suggestive of a therapy that may have far reaching potential in diseases where progesterone has been implicated. The underlying theme for the action of Proellex is one of an agent that is anti-proliferative and pro-apoptotic and not the proliferative effects noticed in the development of some of the selective estrogen receptor modulators.” He further noted that the Company’s pivotal Phase 3 efficacy and long-term safety studies all include endometrial biopsies and these findings will be strengthened by continued observations which should further support Proellex as an effective and safe therapy in the treatment of a variety of female disorders.
Repros Therapeutics Inc. Announces That Proellex® Administered to Patients as Cyclic Therapy to Treat the Symptoms of Uterine Fibroids for Up to 30 Months Shows No Adverse Effects on the Endometrium
THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) today released strong results from its completed extension safety study of Proellex in the chronic treatment of the symptoms associated with uterine fibroids. To date there have been no abnormal histological findings from the endometrial biopsies taken post menses after cessation of drug administration.
As of this release, results from 13 women who had endometrial biopsies post menses following last dose of drug in a two-drug cycle extension study of Proellex in the treatment of symptoms associated with uterine fibroids are available. These women have been exposed to Proellex for one three-month and two four-month drug cycles to help control the symptoms of their uterine fibroids. These three cycles have covered a span of two and one half years which exceeds current FDA guidance for the duration of exposure to hormonal drugs.
The biopsies have been read by a panel of three expert pathologists all of whom will remain blinded to the treatment allocations until all of the final biopsies from this study have been read. The panel is led by Dr. George Mutter, Associate Professor of Pathology at Harvard Medical School, Department of Pathology, Brigham and Women’s Hospital. Dr. Mutter is a leading expert in the interpretation of gynecological histology and pathology.
Results of assessments of the post menses tissues are that of a benign endometrium. While previous end of drug cycle biopsies from these subjects all had histological changes consistent with those induced by progesterone receptor modulators (Proellex class of drugs), none of these post drug cessation biopsies reflected any of those histological changes. These key findings indicate that the effects of Proellex on the endometrium are present during drug exposure and are reversible upon cessation of drug treatment.
Repros has described in previous communications that it had developed a unique approach to dosing with Proellex which treats women for four months (16 weeks) and then stops treatment to create an “off drug interval” until the next menstrual period commences at which time treatment recommences for four months. These cyclical treatments are designed to be used for chronic treatment of symptomatic uterine fibroids and endometriosis. The rationale for this treatment regimen is that most of the reported bleeding events in previous studies occurred after 16 weeks of continuous treatment and were accompanied by endometrial thickening. By allowing a menstrual flow to occur after treatment withdrawal, the endometrium is essentially refreshed and the tendency toward a progressive endometrial thickening eliminated.
Joseph S. Podolski commented, “The importance of these findings can not be overstated. We believe this is a key finding. The consistency of endometrial effects on and off Proellex are strong and suggestive of a therapy that may have far reaching potential in diseases where progesterone has been implicated. The underlying theme for the action of Proellex is one of an agent that is anti-proliferative and pro-apoptotic and not the proliferative effects noticed in the development of some of the selective estrogen receptor modulators.” He further noted that the Company’s pivotal Phase 3 efficacy and long-term safety studies all include endometrial biopsies and these findings will be strengthened by continued observations which should further support Proellex as an effective and safe therapy in the treatment of a variety of female disorders.
About Repros Therapeutics Inc.
Repros Therapeutics focuses on the development of oral small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
Our lead drug, Proellex®, is a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. We are also developing Proellex as a short course pre-surgical treatment for anemia associated with excessive menstrual bleeding related to uterine fibroids. There is no currently-approved effective long-term orally administered drug treatment for uterine fibroids or endometriosis. In the United States alone, 300,000 women per year undergo a hysterectomy as a result of severe uterine fibroids.
Our second product candidate, Androxal®, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. We are developing Androxal for men with low testosterone and adult-onset idiopathic hypogonadotrophic hypogonadism (“AIHH”) with concomitant plasma glucose and lipid elevations, all of which are components of Metabolic Syndrome. We are also developing Androxal for men of reproductive age with low testosterone levels who want to improve or maintain their fertility and/or sperm function while being treated for low testosterone.
Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Repros' ability to raise additional capital in a timely manner and on acceptable terms or at all, Repros’ ability to have success in the clinical development of its technologies, the timing of enrollment and release of data in such clinical studies and the accuracy of such studies, limited patient populations of clinical studies to date and the possibility that final data may not be consistent with interim data and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov. Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please visit the Company's website at http://www.reprosrx.com.
Contacts
Repros Therapeutics Inc., The Woodlands
President & CEO
Joseph S. Podolski, 281-719-3447
Grandpatb,
That after hours sale was a mere 100 shares, much like most of the trades that take place while the market is open. And unlike the DNDN IVillage board these days, this board is an excellent source of information. You can't expect a post about breeding blacks not to ruffle a feathers, and rightly so.
Corpstrat - I should probably put analysts day on my calendar. When is it?
Charmed,
In this post and in #4506 you have stated that we'll be getting the interim endo p2b results by June 30th. Where did you get that from? TIA
Upcoming events?
We have the full biopsy dataset by the end of July? And the two p3 anemia trials by late August/September? What else is coming up? It'd be nice if this information was in the IBox or on the company website. It might be in past presentations, but I'm not sure. Any other big derisking events coming up in the next few months?
Read the 1st and 3rd paragraphs. Dew is plain wrong.
http://www.jstor.org/sici?sici=0091-6765(199802)106%3C81%3ATUNTPE%3E2.0.CO%3B2-%23&cookieSet=1
Testing for Carcinogenicity of Pharmaceuticals
"Historically, the regulatory requirements for the assessment of the carcinogenic potential of pharmaceuticals in the three regions (the European Union (EU), Japan, the United States) provided for the conduct of long-term carcinogenicity studies in two rodent species, usually the rat and the mouse."
http://www.fda.gov/CDER/GUIDANCE/1854fnl.pdf
Wall Street Media Presents Three Exclusive Video Clips from the 2008 FBR Capital Markets Conference
NEW YORK--(BUSINESS WIRE)--Wall Street Media is presenting three exclusive highlights from the presentations of Repros Therapeutics Inc., (Nasdaq: RPRX), SXC Health Solutions Corp., (Nasdaq: SXCI), and CryoLife Inc., (NYSE: CRY), from the 2008 FBR Capital Markets Spring Investor Conference held on May 28-29, 2008 at the Grand Hyatt in New York, NY.
Please visit the following link to view the videos:
http://www.wsmco.com/show.aspx?889_Health_%26amp%3b_tech_video_hig hlights (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
For additional coverage from the 2008 FBR Capital Markets Spring Investor Conference as well as other major investment bank conferences, please visit Wall Street Media at:
www.wsmco.com
Wall Street Media’s coverage includes all major investment bank conferences with more than 20,000 CEO presentations annually as well as interviews with analysts, fund managers, hedge fund managers and market experts.
WSM’s Daily Show features highlight clips of these videos as well as the hosts’ stock picks. The WSM portfolio you will see constantly mentioned may be followed for free at www.covestor.com.
Covestor.com aims to de-institutionalize money management to provide a real-trade sharing service that offers self-directed investors the opportunity to compete with, and be rewarded like, professionals. By sharing the work they already do for themselves, Covestor builds each of its members an institutional grade track record and allows them to track the real portfolios of other proven investors for free.
Contacts
Wall Street Media
Torrey Manz, 212-354-1102
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
May 27, 2008
-----------------------------------------
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Repros Therapeutics, Inc.
File No. 1-15281 – CF#19941
-----------------------------------------
Repros Therapeutics, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibit to a Form 8-K filed on March 20, 2007.
Based on representations by Repros Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit will not be released to the public for the time period specified:
Exhibit 10.3 through March 19, 2017
For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:
Michael McTiernan
Special Counsel
Pharmacological uses and perspectives of heavy water and deuterated compounds.
Can J Physiol Pharmacol. 1999 Feb;77(2):79-88.
Kushner DJ, Baker A, Dunstall TG.
Department of Botany, University of Toronto, ON, Canada. kushner@botany.utoronto.ca
Since the discovery of D20 (heavy water) and its use as a moderator in nuclear reactors, its biological effects have been extensively, although seldom deeply, studied. This article reviews these effects on whole animals, animal cells, and microorganisms. Both "solvent isotope effects," those due to the special properties of D20 as a solvent, and "deuterium isotope effects" (DIE), which result when D replaces H in many biological molecules, are considered. The low toxicity of D20 toward mammals is reflected in its widespread use for measuring water spaces in humans and other animals. Higher concentrations (usually >20% of body weight) can be toxic to animals and animal cells. Effects on the nervous system and the liver and on formation of different blood cells have been noted. At the cellular level, D20 may affect mitosis and membrane function. Protozoa are able to withstand up to 70% D20. Algae and bacteria can adapt to grow in 100% D2O and can serve as sources of a large number of deuterated molecules. D2O increases heat stability of macromolecules but may decrease cellular heat stability, possibly as a result of inhibition of chaperonin formation. High D2O concentrations can reduce salt- and ethanol-induced hypertension in rats and protect mice from gamma irradation. Such concentrations are also used in boron neutron capture therapy to increase neutron penetration to boron compounds bound to malignant cells. D2O is more toxic to malignant than normal animal cells, but at concentrations too high for regular therapeutic use. D2O and deuterated drugs are widely used in studies of metabolism of drugs and toxic substances in humans and other animals. The deuterated forms of drugs often have different actions than the protonated forms. Some deuterated drugs show different transport processes. Most are more resistant to metabolic changes, especially those changes mediated by cytochrome P450 systems. Deuteration may also change the pathway of drug metabolism (metabolic switching). Changed metabolism may lead to increased duration of action and lower toxicity. It may also lead to lower activity, if the drug is normally changed to the active form in vivo. Deuteration can also lower the genotoxicity of the anticancer drug tamoxifen and other compounds. Deuteration increases effectiveness of long-chain fatty acids and fluoro-D-phenylalanine by preventing their breakdown by target microorganisms. A few deuterated antibiotics have been prepared, and their antimicrobial activity was found to be little changed. Their action on resistant bacteria has not been studied, but there is no reason to believe that they would be more effective against such bacteria. Insect resistance to insecticides is very often due to insecticide destruction through the cytochrome P450 system. Deuterated insecticides might well be more effective against resistant insects, but this potentially valuable possibility has not yet been studied.
http://www.ncbi.nlm.nih.gov/pubmed/10535697
BIOTECHNOLOGICAL POTENTIAL OF HEAVY WATER AND DEUTERATED COMPOUNDS
D.J. Kushner1,*, Alison Baker1 and T.G. Dunstall2
1Department of Botany, University of Toronto, Toronto, ON, Canada M5S 3B2; and 2Ontario Hydro Technologies, Toronto, ON, Canada M8Z 5S4
*For offprint requests: Department of Botany, University of Toronto, Toronto, ON, Canada M5S 3B2; fax: (416)978-5878; email: kushner@botany.utoronto.ca
SUMMARY
Some of the environmental, medical, biochemical and other commercial uses of deuterium (D) and heavy water (D2O) are briefly reviewed. Many microorganisms can grow in "pure" (99.6-99.8%) D2O, usually after a period of adaptation. Such organisms can produce a very large number of deuterated compounds.
Deuterated glycerol has interesting potential uses as a precursor of transparent plastics and other compounds. We report experiments on the formation of deuterated glycerol by Dunaliella spp, salt-tolerant algae growing in D2O. These algae produce glycerol as a "compatible solute" when growing in high NaCl concentrations. Although the different species studied did not grow as well in D2O as in H20, the total glycerol production of at least one species was just as high. Our results indicate a new and interesting biotechnological potential for such algae.
Key words: deuterium, heavy water, D2O, glycerol, algae, Dunaliella.
INTRODUCTION
Deuterium (2H or D), the isotope of hydrogen containing two neutrons and one proton, was separated by Urey et al. (1932). D2O makes up a small but significant fraction (ca. 0.015 mol %) of natural water. Its ability to act as a moderator of nuclear reactions led to major industrial efforts to produce it in large quantities. It may be concentrated from natural water by several different methods. These include exchange between deuterated hydrogen (HD), hydrogen sulfide (in the Girdler-Sulfide process, which has been most used), ammonia or methylamine and liquid water or water vapor, coupled with the use of continual enrichment processes to make the end product, 99.8% D2O (Benedict et al., 1981; Miller and van Alstyne, 1994; Rae, 1991). By 1991, sixty years after its discovery, about 29,000 tonnes of D in the form of D2O had been produced, 60% of this in Canada (Rae, 1991).
All methods are carried out on a very large industrial scale, involving large energy utilization. The increase of the cost of D2O from $60 US/kg in 1960 to about $240 US/kg in 1980 was mainly due to the increased costs of energy (Rae, 1991).
Since this conference is largely concerned with the risks of releasing different substances into the environment, it should be stated at the beginning that D2O itself poses little such risk--so long as it has not been used in nuclear reactors. As will be seen below, D2O itself is not toxic to animals, except under
exceptional and very improbable circumstances. It is non-radioactive. The amount of the radioactive isotope, 3H or tritium, found in heavy water, is very low, < 6kBq/kg D2O (< 0.15 µCi/kg D2O), barely above background. However, in nuclear reactors, neutron bombardment may convert D to 3H, so that levels of 0.6 TBq/kg (15 Ci/kg) or more can be reached, an increase of 8 orders of magnitude (Homma and Murase, 1990). This review will not be concerned with hazards of leaks of 3H-containing heavy water or other dangerous substances from nuclear reactors.
As large amounts of D2O became available, very many lines of research were pursued on deuterated compounds, and many uses have been found for such compounds.
Space limitations make it impossible to give comprehensive references for all the points listed. We hope to prepare a bibliography on uses of D, D2O and deuterated compounds to be sent to those requesting it.
Protective and therapeutic uses. Partly because of its intrinsic structure (Katz, 1965), D2O increases the stability of organic molecules, macromolecules, viruses and vaccines. This can have important practical effects when vaccines and other heat-sensitive therapeutic substances must be distributed in developing countries, many of whose districts may lack electricity and refrigeration. A number of patents exist for biostabilizing ability of heavy water. These describe increased thermal and microbial stability and slower disaggregation of certain macromolecules (e.g., Crainic and Simpson, 1994). The presence of 95% D2O was found equivalent to a 4-5C reduction in storage temperature relative to H2O, for macromolecular pharmaceuticals such as vaccines; as little as 7-25% D2O helps prevent protein denaturation. D2O medium has been recommended for storing organs, tissues, tissue parts, proteins or enzymes, sera and blood preparations and for the perfusion of organs intended for transplants (Wenzel, 1974), microorganisms and enzymes (Hamaya and Horikoshi, 1989), and hydrolysable compositions such as alpha-hydroxy-carboxylic acids (especially benactyzine) (Teva Pharm. Ind. Ltd. 1989).
Heavy water is also cryoprotective and may shield erythrocytes and other cells, cell constituents, organ-parts or organs against damage by low temperature (<-26C) storage (Boehringer Sohn C H GMBH, 1976).
Though D2O stabilizes proteins and other macromolecules, it does not always make living cells more heat-stable, and may make them less so (reviewed by Unno et al., 1989). The latter effect may be partly due to the lowered ability of deuterated cells to synthesize heat shock proteins and other chaperoning (Unno and Okada, 1991; 1994; Yokogaki et al., 1995). Some direct therapeutic uses of heavy water have been explored, in both animals and humans. Non-toxic levels of heavy water reduce induced hypertension and associated changes in rats (Vasdev et al., 1993; 1994). A patent has been obtained for the use of heavy water in treating human subjects (Liepins, 1993).
Boron neutron capture therapy (BNCT) is used to treat tumors, especially brain tumors, by neutron irradiation of boron-containing compounds bound to malignant cells. Subsequent emission of -particle and other radioactive rays selectively kills these cells. The degree of neutron penetration into tissue, which limits this method, can be greatly increased if the patient's brain is "loaded" with heavy water (Hatanaka, 1989, 1991).
Heavy water has been widely used in measurements of body water space, in children and in adults at various stages of nutrition and exercise. Many human subjects have been injected with or have swallowed a few ml (often 0.1 ml per kg body weight) of heavy water. This increases the D2O content in the blood from 150 to about 300 ppm, which subsequently decays to the normal level with a half-life of a few days (Coward, 1979). The water space of animal bodies may be determined by the degree of dilution of the heavy water, which can be measured with great sensitivity.
The widespread use of heavy water in clinical studies and treatments without reported adverse effects implies that it is not very toxic to humans. This is also suggested by animal experiments, in which toxic effects did not begin to appear until the D content of blood and body fluids and tissues was over 20% (Katz, 1960; 1965; Thomson, 1963). To attain such a concentration and adult human weighing about 70 kg would have to drink rapidly more than 10 L D2O.
Microbial growth in D2O. D20 is even less toxic to microorganisms than to multicellular creatures. Some bacteria and algae can grow in "pure" (normally 99.6-99.8%) D2O, though usually more slowly than in H2O, and after a period of adaptation. Even more complex cells, such as protozoa can grow in quite high concentrations (70-100% D2O) (Katz, 1965; Thomson, 1963). Microorganisms that can grow in pure D2O include, but are not limited to, the algae, Chlorella and Scenedesmus (Katz, 1965; Unno et al., 1987, 1989) and, as this report shows, the salt-tolerant Dunaliella species. Bacteria include Escherichia coli, Pseudomonas putrefaciens, Serratia marcescens (Katz, 1965; Thomson, 1963; Vanatulu et al., 1993), and extremely halophilic archaebacteria (Crespi, 1982). Among yeasts and fungi, Torula and Aspergillis spp. have been grown in pure D2O (Thomson, 1963), as have methylotrophic Candida spp. (Haon et al., 1993). In most cases, a period of "training" or adaptation is required at lower D2O concentrations before cells can grow in the pure substance; mechanisms involved in such adaptation have hardly been studied. Microorganisms growing in D2O can provide a large number of deuterated compounds. Algae that have grown in D2O can provide biomass to serve as feedstock for the growth of heterotrophic microorganisms (Crespi, 1988).
Environmental and pollutant studies. Determination of the natural occurrence of deuterium and other stable isotopes is a powerful means for investigating past and current environmental changes in the Earth's atmosphere and hydrosphere. The isotopic composition of trace atmospheric constituents provides information on sources, sinks and transformations of these compounds and, since the distribution of environmental isotopes is governed by environmental conditions, they can be used to examine both natural and anthropogenic influences on climatic variation (Kaye, 1992; Rozanski and Gonfiantini, 1990; Bowen et al., 1990). Stable isotopes of H, O and C have been used to assess the atmospheric methane inventory (Levin and Doerr (1991), to evaluate the source of water vapour in the upper troposphere (Smith, 1992), and by studies of the deuterium profile of an Antarctic ice core, to assess atmospheric temperature changes over 160,000 years (Jouzel et al., 1987).
Other such studies have provided valuable information about the steady-state characteristics and past changes in the water cycle, including information on ground- and soil-water sources and movement (Bowen et al., 1990; Wood and Sanford, 1995; Sadler et al., 1992; Jacob et al., 1992), lake hydrology (Krabbenhoft et al., 1991; Aly et al., 1993) and evaporation rates in deserts (Sonntag et al., 1984; Nativ et al., 1995).
D2O and D218O (double-labelled water) have been used to study snowmelt contributions to spring runoff in acid-stressed headwater streams (Wels et al., 1988), in differentiating different source waters from background groundwater and for determining probable contaminant sources associated with a landfill operation (Mohr et al., 1992), and for estimating native interstitial water and moisture migration in petroleum deposits (Fjerstad et al., 1993; Karasev and Dubinchuk, 1977).
Evapotranspiration, whose magnitude is influenced by growing-season precipitation, humidity and temperature, enriches D and 18O in leaf water of plants (Cooper and DeNiro, 1989; Ramesh et al., 1985). D/H ratios of tree sap can be used to determine the relative contribution of summertime rains and groundwater as the tree's source water (White et al., 1985). Isotopic (2H and 18O ratios in plant leaves can be used to determine sources of water, water movement and changes of evaporation patterns during the day (Bariac et al., 1994a and b).
D2O has also been used to follow water behaviour in materials. Water distribution in concrete samples has been spatially resolved using magnetic resonance imaging, with D2O employed as a tracer (Kaufmann et al., 1992).
Stable isotopes have also been applied to the investigation of mineral resources (Toulhoat et al., 1990; Wilson, 1989; Brandt et al., 1986). D, 13C and 18O have been used to establish the relative contributions of thermogenic versus biogenic processes to the formation of natural gases in petroleum deposits (Feinstein et al., 1993; Ahmad and Alam, 1992). After organic matter is formed, environmental changes have minimal effect on 13C composition, but can greatly modify deuterium content (Missbach and Schatze, 1987).
Deuterated molecules make useful, very sensitively-detected tracers for environmental pollution. To take only one example among many, Thierrin et al. (1995) used deuterated benzene, toluene, p-xylene and naphthalene to study movement and degradation of these compounds in a plume of contaminated groundwater.
Sources of foods and organic chemicals. The D/H ratios of hydrocarbons can indicate the origin of wines and spirits, petroleum products, rubber, as well as sugar or ethanol in foods and beverages (Martin et al., 1986; Martin and Martin, 1983, 1991). Remaud et al., (1992) used information on site-specific D content and overall 13C content of acetic acids to differentiate between natural and synthetic (fossil origin) vinegars, or mixtures of the two.
H2O leaves plants more readily than D2O, and hence plant juices will be richer in D2O than water entering the plant. This can be used to distinguish fruit juices reconstituted from concentrates from the juices found in Nature (Roth, 1993).
Biochemical and structural studies. A vast amount of chemical and biochemical work has taken advantage of the fact that D from D2O can readily exchange with H atoms of organic molecules, especially those bound to O and N atoms. The exchangeability can show when certain groups in proteins and antigen/antibody complexes, are exposed to water (Englander and Mayne, 1992: Paterson et al., 1990). Since C-D bonds are much stronger than C-H bonds, relative reactivity of deuterated compounds can help determine to what extent C-H bond breakage is normally involved. Other aspects of these "deuterium isotope effects" have been discussed in great detail (Cleland et al., 1976; Gillette et al., 1994; Klein et al., 1995; Vanoni et al., 1990). Deuterated compounds are extensively used in spectrophotometric studies. Since H2O interferes with nuclear magnetic resonance (NMR) signals, this powerful technique for studying molecular structure is often applied to compounds suspended in D2O or deuterated organic solvents (Hore, 1989; Markley, 1989; LeMaster, 1990.) Deuterated proteins and other macromolecules may be especially valuable for NMR and neutron diffraction studies (Rösch, 1986; Vanatulu et al., 1993).
Substances produced by deu-terated microorganisms. Kyle et al. (1988) described growth of algal species on 99% D2O. A Neochloris sp. was able to grow well and produced more lipid than during growth in H2O. Such algae were of special interest as sources of deuterated lubricants. These were shown by previous workers to be many-fold more resistant to thermooxidative breakdown than hydrogenated lubricants. Preparation of deuterated lipids by treating the unsaturated forms with D2 gas is a much more expensive process than the biological process described. Nevertheless, a market has still not developed for deuterated lipids, largely because their cost is still high. Haon et al. (1993) showed that methyltrophic yeasts growing in D2O were good sources for deuterated ergosterol.
Deuterated drugs. A great number of deuterated drugs have been synthesized, in order to study their movement and metabolism in bodies of humans and other animals. Of special interest are drugs whose therapeutic properties are changed by deuteration. These include amphetamines, which are more readily transported into the brain in the deuterated form (Wenzel, 1989); halogenated anaesthetics, such as selvoflurane, which, when deuterated are no longer oxidized to toxic forms within the body (Baker et al., 1993), and certain antimicrobial compounds [long-chain fatty acids (Abrahamson et al., 1982) and D-fluorophenylalanine (Merck and Co., 1977)] whose deuterated forms are not oxidized by the affected microorganism arid hence are toxic for longer times
Other uses for D and deuterated compounds. Synthetic deuterated fibres may be incorporated in currency notes. This provides a method of tagging large amounts of currency (for example from drug smuggling) whose transfer is of dubious legality (Muller 1991).
Very recently it was found that using D2 instead of H2 to coat metal oxide semi-conductor transistors (such as computer chips) extends their lifetimes many-fold (Lyding et al., 1996) though possibly not enough to account for the changes in technology and fashion that make the most modern computers so soon obsolete.
Deuterated compounds for optical technology. In recent years patents have been obtained for the use of deuterated polymers and other compounds in laser and optical technology. These include deuterated 4-'nitrobenzylidene-3-halo -alkanoylamino-4-methoxy aniline crystals for nonlinear optical devices used for optical communication or information processing and optical recording material (Toray Ind. Inc. 1995), deuterated N, N'-diamino dicarboxylic acid amides with similar uses (Mitsui Petrochem. Ind. Co. Ltd., 1994), deuterated polyvinyl alcohols or polymethaerylic acids for optical recording devices (Iwamoto et al., 1992) and deuterated 1-arginine phosphate frequencyconversion crystals for use in lasers (Barker et al., 1992). Deuterated acrylate polymers have been claimed to be specially useful in optical fibres (Kitahara et al., 1984; Mitsubishi Rayon KK, 1984).
We have been espeially interested in the use of microorganisms as sources of deuterated compounds. Our experiments have involved the formation of a potentially useful product, deuterated glycerol, by salt-tolerant algae growing in heavy water.
The algae selected for this study were different species of the genus Dunaliella, including Dunaliella tertiolecta, D. salina and D. bardawil. These are unicellular eukaryotic green algae, motile by a pair of anterior flagella. Dunaliella species are found in the sea and many salt lakes, such as the Dead Sea in Israel, the Great Salt Lake in Utah, USA, and in many salterns where salt is prepared by evaporating sea water. They have the characteristic, in common with other salt-tolerant algae and yeasts, of producing high concentrations of glycerol as a compatible solute, that is a solute which maintains the internal osmotic pressure equivalent to that outside the cell and also permits the cell's internal enzymatic and other processes to function. ln high salinity, the internal glycerol can make up to 85% of the dry weight of the cell (Brown, 1990; Javor, 1989). If these algae can grow in pure D2O (with CO2 as a carbon source), their glycerol (and other molecules) should exist in a deuterated form.
Biological production of deuterated glycerol was of special interest because this substance can be converted to deuterated acrylic acid by the following steps, catalyzed by bacterial enzymes:
Glycerol Ô Propane di-ol Ô 3-hydroxypropionaldehyde Ô Acrylic acid (CH2 =CH-COOH) (Vancauwenberge et al., 1990).
MATERIALS AND METHODS
Species studied. Dunaliella bardawil was originally obtained from the American Type Culture Collection (ATCC 30861). D. tertiolecta Butcher (UTEX LB 000) was obtained from Dr. J. Hellebust, Department of Botany, University of Toronto. D. salina (UTEX LB 635) was obtained from the University of Toronto Culture Collection (UTCC). Some studies were also carried out on another salt-tolerant alga, Stephanoptera sp. (UTEX LB 635) obtained from UTCC. However, this grew very poorly in D2O and produced little glycerol, so that results with it are not given.
Cultures were grown in 50 mL liquid Dunaliella culture medium of Ben-Amotz et al. (1989), with NaCl concentrations of 0.5 - 3.5 M, as specified, in 150 mL cotton-plugged Erlenmeyer flasks; the inoculum was, at first, 2 mL of a culture in H2O and 10 mL of a culture in D2O (because of lower growth in the latter); as the cultures became adapted to D2O smaller inocular were used. Cultures were maintained in a growth chamber at 26C on a 14 hr light/ 10 hr dark schedule. Irradiance was by combined cool white fluorescent light and incandescent light at 180 µEm-2s-1.
Glycerol was usually assayed as a diol after oxidation with periodate (Ben-Amotz and Avron, 1978). In a few experiments, a more specific method involving coupled glycerokinase and glycerophosphate dehydrogenase (Wieland, 1983) was used. Both gave the same results, showing that the di-ol produced was indeed glycerol.
RESULTS AND DISCUSSION
Adaptation of Dunalielia spp. to heavy water. None of the species tested could grow in 100% (actually 99.6%) D2O when first tested. However, after a process of adaptation involving culturing in higher and higher D2O concentrations, all the Dunaliella spp were able to grow in 100% D2O. This process is shown in Figure 1 for D. tertiolecta, and a similar process occurred with the other two species. As the figures shows, with this alga, good growth occurred in 25% and 50% D2O, on inoculation from H2O. This growth was at the same level as in H2O (not shown). No growth occurred when cells were transferred from H2O to 75% or 85% D2O (not shown), but cells cultured in 50% D2O could grow in these higher concentrations. Preculture in yet higher D2O concentrations led to the ability to grow in still higher concentrations; thus 85% D2O inoculated from 85% D2O permitted better growth than the same concentration inoculated from 50% D2O. Though growth finally occurred in 100% D2O, this was considerably slower than in lower D2O concentrations or in H2O. This was also true of the other species, after adaptation (Figure 2).
As Figure 3 shows, the relative response to different NaCl concentrations of D. bardawil was similar in H2O and D2O, and similar results were found for the other Dunaliella spp (not shown).
Increasing two of the essential nutrients, SO4-- and NO3-, in amounts that increased the level of these substances in the medium five-fold, had no significant effect on growth of D. bardawil in D2O (not shown).
Effects of external NaCl concentration on glycerol production. This was studied in all three Dunaliella spp; results are summarized in Tables 1 and 2. D. bardawil was studied in more detail than the other species. A somewhat different relation between NaCl concentration and intracellular glycerol production was observed in the two kinds of water. In H2O there was an almost linear relationship between medium salt concentration and internal glycerol, with most glycerol being found in the cells at the higher salt concentration. In D2O, such a relationship was not observed, but most internal glycerol was produced at the salt concentrations where the cells were at the most stress (i.e., at the lowest and highest NaCl concentrations permitting growth.) However, total glycerol production also followed the external NaCl concentration. In general, more external glycerol was found in cultures growing in D2O than in H2O. Though growth was considerably less in D2O than H2O, total glycerol production was approximately equivalent in both cultures of D. bardawil.
Less total glycerol was produced in D2O than H2O by D. tertiolecta growing in 0.5 M NaCl and D. salina growing in 2.0 M NaCl. However, the amount of total glycerol produced per cell by both algae was clearly greater in D2O than in H2O.
Our experiments have shown that algae which can grow in the relatively extreme conditions of high NaCl concentration are still able to do so in 100% D2O. They also show that during this process, the algae produce substantial amounts of deuterated glycerol, a potentially valuable product. Indeed, in terms of cell growth, the algae produce more than they would in H2O. These results add further support to the idea that there are interesting biotechnological potentials in such microorganisms.
http://nbiap.biochem.vt.edu/brarg/brasym96/kushner96.htm
I intended to but got my time zones mixed up. Did he say anything about Recothrom sales?
At what point will proellex have been de-risked enough for the big pharma's to start bidding on a deal? Will they wait til the anemia p3's are finished in a couple of months, or do they wait til the p3's from the other indications are available?
Dew - care to end speculation that your actions are responsible for walldiver's resignation from moderating the DNDN board?
Posted by: walldiver
In reply to: None
Date:4/13/2008 11:52:04 PM
Post #of 5696
OT-Just want everyone to know that I've resigned as moderator for this board. The board became co-opted by another moderator and there was nothing I could do about it.
Joe's aggressive timelines?
I was surprised by the short interest, but I suppose I shouldn't have been. RPRX increased almost $1.50 during those two weeks, but has since given up those gains.
Short interest down 22.12%
Repros Therapeutics Inc. - Common Stock
Settlement Date Short Interest Percent Change Average Daily Share Volume Days to Cover
03/31/2008 979,155 (22.12) 113,826 8.60
03/14/2008 1,257,186 8.24 115,126 10.92
02/29/2008 1,161,472 0.86 59,932 19.38
02/15/2008 1,151,580 (9.95) 55,279 20.83
01/31/2008 1,278,783 (7.91) 77,639 16.47
01/15/2008 1,388,551 17.07 61,643 22.53
12/31/2007 1,186,120 35.63 128,710 9.22
12/14/2007 874,526 57.68 273,273 3.20
11/30/2007 554,631 39.90 111,740 4.96
11/15/2007 396,460 32.81 94,349 4.20
10/31/2007 298,519 16.80 136,913 2.18
10/15/2007 255,571 (15.32) 80,905 3.16
09/28/2007 301,798 (5.88) 61,483 4.91
09/14/2007 320,665 (31.02) 79,199 4.05
08/15/2007 464,838 (26.16) 79,171 5.87
07/13/2007 629,553 10.55 86,216 7.30
06/15/2007 569,458 (4.16) 133,646 4.26
05/15/2007 594,163 41.94 140,912 4.22
04/13/2007 418,612 19.02 140,387 2.98
http://www.nasdaqtrader.com/trader.aspx?id=ShortInterest
Whither Thrombin?
Tuesday, April 01, 2008
On seeing today’s New York Times article “Seeking Alternative to Animal-Derived Drugs,” my first thought was that it could’a/should’a mentioned the January 2008 approval of the first recombinant human thrombin, which has the potential to replace bovine- and plasma-derived equivalents now on the market. But as noted in stories in IN VIVO and The RPM Report this month, ZymoGenetics, the developer of recombinant thrombin, can’t seem to catch a break these days, especially from Wall Street analysts.
ZymoGenetics saw its recombinant thrombin, Recothrom, the first product it decided to commercialize on its own, as a way to balance the risk in its portfolio. Management has noted that all previous recombinant clotting factors -- along with insulin, hGH and a host of women's health hormones -- had succeeded in clinical trials and in the market. When it initiated the program, “we thought the major risk wouldn’t be clinical trials or commercial, but whether we could manufacture with an appropriate cost of goods,” says CEO Bruce Carter. Bovine thrombin, sold by King Pharmaceuticals, carries a Black Box warning about the severe bleeding risks associated with potential antibody formation. It’s also blocked from the market in Europe because of fears around potential transmission of Mad Cow disease.
But despite the implicit logic that a recombinant product is safer, for various reasons, it’s near impossible to directly correlate bleeding and bovine thrombin, and therefore there's no baseline with which to measure improvement in patient outcome, which poses a problem for reimbursement. As a surgical adjunct, recombinant thrombin also has to make its way through hospitals’ Pharmacy & Therapeutics Committees before it’s stocked, which takes time.
Plus, because Recothrom is a biotech product (and as a biotech company, ZymoGenetics is covered by biotech analysts with little experience following the launch of such a device-like medical product), there appears to be even more uncertainty over how to gauge the product’s trajectory in the market.
It’ll take time to prove the value proposition. Oppenheimer’s Kevin DeGeeter, for example, in a March 31 note, perhaps unfairly used Recothrom’s modest February sales ($26,164) to say that while it’s still very early in the product launch, there are concerns that conversion from bovine-derived thrombin “will take much longer than the Street expects.”
In any event, it is true that ZymoGenetics is in a tough position in a tough biotech stock environment, as it starts to be judged less on the value of its pipeline than on its commercial performance. It'll also be facing a cash crunch later this year and, with hindsight, probably should have financed in 2007 instead of waiting for a potential bump in stock price on the Recothrom approval.
The company likely could have done a better job of prepping analysts for a slow conversion process and launch, instead of believing validation would have come more easily after it found a partner (Bayer) to help with the US launch and open up the European market, and got the drug through FDA with a broad label despite analysts' worries over that.
That said, a tipping point favoring a safer if somewhat more expensive thrombin could come anytime, especially in this politically charged, safety-first health care environment.
http://invivoblog.blogspot.com/2008/04/whither-thrombin.html
To see which HFs and MFs have been adding/ dumping, check this out:
http://www.mffais.com/rprx.html
Nerf & Io - I think it would appropriate to use your veto powers to ban Dew from the board. He contributes nothing and actively seeks to start arguments over and over again. Toss the garbage out.
Recothrom was only approved on January 17th and you are pronouncing it a failure based on February sales numbers! Hospital P&T committees meet what, once a quarter? And then there's the bovine thrombin inventory they need to use up. The sales people need to convert clients, etc. Unbelievable.
Also, Omrix's human thrombin was approved in late August and as far we know they haven't sold a vial yet. Give it til late 2008 before deciding if Recothrom is a success or not. At this point in time, we simply don't know.
> Really guys, the more you stand on thse pedandic arguments the more you seam like robot pumpers.
Really guys, the more you stand on these pedantic arguments the more you seem like robot pumpers.
Yep - the bashers are human. Surely a robot would use spellcheck?
Amen to that. The guy is a goldmine of biotech knowledge, but all too often resembles the lowest form of life - the messageboard basher. His posts here belong on the Yahoo boards along with those of the other nutjobs.
Corp,
It's not up on the RPRX website yet - how did you just listen?
Another 50k block went through. Wouldn't be surprised to see a new Form 4 from Efficacy in the next few days.
Short Interest up 100k
Repros Therapeutics Inc. - Common Stock
Settlement Date Short Interest Percent Change Average Daily Share Volume Days to Cover
02/29/2008 1,161,472 0.86 59,932 19.38
02/15/2008 1,151,580 (9.95) 55,279 20.83
01/31/2008 1,278,783 (7.91) 77,639 16.47
01/15/2008 1,388,551 17.07 61,643 22.53
12/31/2007 1,186,120 35.63 128,710 9.22
12/14/2007 874,526 57.68 273,273 3.20
11/30/2007 554,631 39.90 111,740 4.96
11/15/2007 396,460 32.81 94,349 4.20
10/31/2007 298,519 16.80 136,913 2.18
10/15/2007 255,571 (15.32) 80,905 3.16
09/28/2007 301,798 (5.88) 61,483 4.91
09/14/2007 320,665 (31.02) 79,199 4.05
08/15/2007 464,838 (26.16) 79,171 5.87
07/13/2007 629,553 10.55 86,216 7.30
06/15/2007 569,458 (4.16) 133,646 4.26
05/15/2007 594,163 41.94 140,912 4.22
04/13/2007 418,612 19.02 140,387 2.98
03/15/2007 351,709 26.96 131,899 2.67